- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.10. | H.C. Wainwright bestätigt Kaufempfehlung für Eupraxia nach starken Studiendaten | 1 | Investing.com Deutsch | ||
| 02.10. | H.C. Wainwright reiterates Buy rating on Eupraxia Pharmaceuticals stock | 1 | Investing.com | ||
| 30.09. | Eupraxia Reports Encouraging Safety And Efficacy Data From Eosinophilic Esophagitis Study | 1 | Benzinga.com | ||
| 30.09. | Eupraxia Pharmaceuticals stock maintains Overweight rating at Cantor Fitzgerald | 3 | Investing.com | ||
| 29.09. | Eupraxia reports positive data from highest dose cohort in EoE trial | 1 | Investing.com | ||
| EUPRAXIA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 29.09. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs | 419 | GlobeNewswire (Europe) | Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients... ► Artikel lesen | |
| 29.09. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 25.09. | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals closes $80.5-million offering | 1 | Stockwatch | ||
| 24.09. | Eupraxia Pharmaceuticals schließt Kapitalerhöhung über 80,5 Millionen US-Dollar ab | 1 | Investing.com Deutsch | ||
| 24.09. | Eupraxia pharmaceuticals raises $80.5 million in public offering | 2 | Investing.com | ||
| 24.09. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option | 307 | GlobeNewswire (Europe) | VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 23.09. | Eupraxia Pharmaceuticals: Aktie fällt nach Platzierung einer 70-Millionen-Dollar-Kapitalerhöhung | 2 | Investing.com Deutsch | ||
| 23.09. | Eupraxia Pharmaceuticals stock falls after pricing $70 million offering | 1 | Investing.com | ||
| 23.09. | Eupraxia Pharmaceuticals Inc: Eupraxia prices shares of offering at $5.50 (U.S.) | 1 | Stockwatch | ||
| 23.09. | Eupraxia Pharmaceuticals prices $70M share offering | 1 | Seeking Alpha | ||
| 23.09. | Eupraxia platziert Kapitalerhöhung über 70 Mio. US-Dollar zu 5,50 US-Dollar je Aktie | 1 | Investing.com Deutsch | ||
| 23.09. | Eupraxia prices $70 million public offering at $5.50 per share | 1 | Investing.com | ||
| 23.09. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares | 204 | GlobeNewswire (Europe) | VICTORIA, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 23.09. | Eupraxia Pharmaceuticals Inc: Eupraxia files preliminary prospectus for offering | 1 | Stockwatch | ||
| 22.09. | Eupraxia Pharmaceuticals plant öffentliche Platzierung von Stammaktien | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 6,680 | 0,00 % | Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event | ||
| NUVALENT | 97,97 | 0,00 % | Stifel initiates coverage on Nuvalent stock with Buy rating | ||
| DISC MEDICINE | 87,17 | -3,04 % | Disc Medicine Inc: Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner's National... ► Artikel lesen | |
| QIAGEN | 41,860 | +1,25 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 71,19 | -2,31 % | Tarsus Pharmaceuticals stock price target raised to $88 from $72 at H.C. Wainwright | ||
| CG ONCOLOGY | 43,590 | +5,14 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 20,880 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| IMMUNOVANT | 19,220 | 0,00 % | Truist Securities initiates Immunovant stock with Hold rating, $16 target | ||
| SUMMIT THERAPEUTICS | 20,030 | 0,00 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| RANI THERAPEUTICS | 2,240 | 0,00 % | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 175,21 | 0,00 % | Praxis Precision Medicines prices $525M public offering | ||
| KEROS THERAPEUTICS | 15,190 | 0,00 % | Keros Therapeutics launches $194.4 million share repurchase tender offer | ||
| ARCTURUS THERAPEUTICS | 21,510 | +4,11 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| BEAM THERAPEUTICS | 30,630 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| IMMUNOME | 16,250 | 0,00 % | Where Immunome Stands With Analysts |
EUPRAXIA PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,740 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EUPRAXIA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.